Skip to main content
Medesis Pharma S.A. logo

Medesis Pharma S.A. — Investor Relations & Filings

Ticker · ALMDP ISIN · FR0010844464 LEI · 969500C15M96P00UR648 PA Manufacturing
Open in API
Filings indexed 118 across all filing types
Latest filing 2023-04-27 Report Publication Anno…
Country FR France
Listing PA ALMDP

About Medesis Pharma S.A.

https://www.medesispharma.com/

Medesis Pharma is a clinical-stage pharmaceutical biotechnology company focused on developing treatments for serious diseases using its proprietary AONYS® drug delivery platform. The AONYS® technology is a micro-emulsion designed for buccal (oral) administration, enabling the intracellular delivery of various therapeutic molecules, including metal ions, interfering RNAs, and peptides. A key feature of the platform is its ability to transport active ingredients across the blood-brain barrier, making it a promising approach for neurological disorders. The company's development pipeline addresses diseases with high unmet medical needs, including neurodegenerative conditions like Alzheimer's disease and therapies for individuals exposed to nuclear radiation.

Recent filings

Filing Released Lang Actions
MEDESIS PHARMA : Mise à disposition du Rapport Financier Annuel 2022
Report Publication Announcement Classification · 100% confidence The document is a short press release (2316 characters) titled 'Mise à disposition du Rapport Financier Annuel 2022' (Availability of the 2022 Annual Financial Report). It explicitly states that the company has made the report available to the public and filed it with the AMF. Following the 'Menu vs Meal' rule, since this is an announcement of the publication of a report rather than the report itself, it is classified as a Report Publication Announcement (RPA).
2023-04-27 French
MEDESIS PHARMA : Rapport Financier Annuel 2022
Annual Report Classification · 95% confidence The document is a comprehensive 'Rapport de gestion' (Management Report) for Medesis Pharma for the fiscal year ending December 31, 2022. It includes detailed sections on company activity, R&D programs, financial situation, governance, and reports from the board and auditors. Since it contains substantive financial data, management analysis, and audit reports for a full fiscal year, it functions as an Annual Report (10-K equivalent in this context). FY 2022
2023-04-27 French
MEDESIS PHARMA : 2022 FULL-YEAR BUSINESS AND EARNINGS
Earnings Release Classification · 95% confidence The document is a press release titled '2022 FULL-YEAR BUSINESS AND EARNINGS' from Medesis Pharma. It provides a summary of financial results, including a table of corporate accounts, and discusses business operations, clinical programs, and outlook. While it contains financial data, it is structured as a press release (Earnings Release) rather than a full annual report or a formal interim financial report. It fits the definition of an Earnings Release (ER) as it provides initial highlights of financial performance for the period. FY 2022
2023-04-17 English
MEDESIS PHARMA : ACTIVITÉS & RÉSULTATS ANNUELS 2022
Earnings Release Classification · 95% confidence The document is a press release titled 'ACTIVITÉS & RÉSULTATS ANNUELS 2022' issued by Medesis Pharma. It provides a summary of annual financial results, including a table of key figures, and discusses business activities, clinical program progress, and future outlook. While it contains financial data, it is structured as a corporate press release (Communiqué de presse) rather than a full statutory annual report (10-K). According to the classification rules, an initial announcement of periodic financial results that highlights key figures is classified as an Earnings Release (ER). FY 2022
2023-04-17 French
MEDESIS PHARMA SIGNS A PARTNERSHIP WITH PARTNER INTERNATIONAL, WORLD LEADER IN TRANSACTIONS BETWEEN BIOTECHS AND PHARMACEUTICAL LABORATORIES
Regulatory Filings Classification · 95% confidence The document is a press release announcing a strategic partnership between MEDESIS PHARMA and PARTNER INTERNATIONAL concerning business development and potential licensing opportunities. This type of announcement, which details a significant business agreement or strategic move that is not a standard financial filing (like 10-K, ER, or IR), typically falls under general corporate news or regulatory updates. Since it is not a specific financial report, management change, dividend notice, or capital event, and it is a formal announcement, the most appropriate category is the general regulatory/corporate announcement fallback, RNS (Regulatory Filings). It is too specific for a general 'LTR' (Legal Proceedings) or 'CAP' (Financing Update), and it is not a transcript, presentation, or formal report.
2023-04-04 English
MEDESIS PHARMA SIGNE UN PARTENARIAT AVEC PARTNER INTERNATIONAL, LEADER MONDIAL DES TRANSACTIONS ENTRE BIOTECHS ET LABORATOIRES PHARMACEUTIQUES
Regulatory Filings Classification · 86% confidence The document is a press release ("COMMUNIQUÉ DE PRESSE") announcing a strategic partnership between MEDESIS PHARMA and PARTNER INTERNATIONAL regarding drug development and licensing activities. This type of announcement, detailing business development, strategic alliances, or potential future financing/licensing deals, fits best under the category of M&A Activity (TAR) or potentially Capital/Financing Update (CAP) if the focus was purely on funding. However, since it explicitly describes a partnership aimed at expanding markets and securing licenses/deals for drug candidates, it strongly relates to corporate transactions and strategic alliances, which aligns closely with the scope of M&A Activity (TAR), which covers merger proposals or takeover bids, often encompassing major strategic deals. Given the options, and the nature of the announcement being a significant business transaction/alliance, TAR is the most appropriate fit, although it is not a perfect match for a pure M&A event. If TAR is interpreted strictly as M&A, then CAP (Capital/Financing Update) is the next best fit as it involves accelerating programs and generating new funding sources. Let's re-evaluate the definitions. TAR is for 'merger proposals or takeover bids'. This is a partnership for licensing/market expansion. CAP is for 'fundraising, financing activities, or capital structure changes'. The partnership aims to generate new funding sources and accelerate programs, which is a form of strategic financing/deal-making. Given the focus on business development and potential future transactions rather than immediate capital raising or a formal merger, I will classify this as a general corporate announcement that doesn't fit the specific financial reports (10-K, IR, ER) or governance documents. Since it is a press release announcing a major business development (partnership), and it is not a formal regulatory filing like 10-K or a specific report, it falls closest to a general announcement. However, looking at the options, 'TAR' (M&A Activity) is often used broadly for significant corporate transactions. If we must choose the best fit among the specific codes, and recognizing that partnerships often precede or are related to M&A/licensing deals, TAR is plausible. If we consider it a general business update, RNS (Regulatory Filings/Miscellaneous) is the fallback. Given the high-value nature of the partnership described (biotech licensing/deal sourcing), I lean towards TAR as the closest strategic corporate action category, but RNS is also a strong candidate if TAR is too narrow. Since the document is a press release announcing a strategic business deal, and it is not a formal financial report, I will select RNS as the most appropriate general regulatory/corporate announcement category when specific transaction codes (like M&A) don't perfectly apply to a partnership announcement, adhering to the principle that press releases announcing business developments often fall here if a better fit isn't available. Reconsidering: The document is a press release announcing a strategic partnership for licensing and market expansion, which is a significant corporate transaction. This is often grouped with M&A activity in broader databases. I will classify it as TAR (M&A Activity) as it represents a major strategic transaction/alliance, even if it's not a merger itself.
2023-04-04 French

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.